title: Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion.
abstract: We describe a 38 year old hemophilia A patient with a factor VIII inhibitor who was admitted to our Hematology Department in January 2001 with a seriously infected and bleeding perianal ulcer. To treat infection and bleeding the patient received broad spectrum antibiotics and recombinant activated factor VII (rFVIIa) (Novoseven(R)) for about 1 month (see detailed time of administration and dosing schedule of rFVIIa further in text). Eighteen days after his last rVIIa infusion the patient developed an ultrasound proven right calf vein thrombosis. In the whole period of admission, preceding the thrombotic event the patient biologically showed a picture of severe systemic inflammatory disease as indicated by persistent increased levels of D-dimer and fibrinogen (table). It is an interesting point of discussion whether the calf thrombosis was provoked as a consequence of rFVIIa infusion (with symptoms 18 days after the last infusion) or as a consequence of long-standing immobilization and severe inflammatory disease immobilization and severe infection are conditions well known for promoting venous thromboembolic disease.
authors.affiliation: Laboratory of Hematology and Hemostasis, Antwerp University Hospital, Edegem, Belgium. marc.van.der.planken@uza.be
authors.forename: M G
authors.initials: MG
authors.lastname: Van der Planken
authors.forename: W
authors.initials: W
authors.lastname: Schroyens
authors.forename: F
authors.initials: F
authors.lastname: Vertessen
authors.forename: J J
authors.initials: JJ
authors.lastname: Michiels
authors.forename: Z N
authors.initials: ZN
authors.lastname: Berneman
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D005167:Factor VII / Q000008:administration & dosage / Q000009:adverse effects*; D015942:Factor VIIa; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007103:Immobilization / Q000009:adverse effects; D007239:Infections / Q000150:complications* / Q000188:drug therapy; D007518:Isoantibodies / Q000097:blood; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D020246:Venous Thrombosis / Q000209:etiology*
chemical_list: D000900:Anti-Bacterial Agents; D007518:Isoantibodies; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa